Contraline Raises $92.5M Series B for Male Contraceptive

Fundraise Insider tracks newly funded startups each week and delivers verified C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Contraline, a clinical-stage biotech company based in Charlottesville, Virginia, has closed a $92.5 million Series B financing. The round, announced on June 2, 2026, was co-led by BVF Partners and RA Capital Management, with participation from GV, Lumira Ventures, Invus, and other new and existing investors.

The company develops novel male contraceptives. Its lead candidate, NES/T, is a once-daily topical gel that combines the synthetic progestin segesterone acetate, known as Nestorone, with testosterone. The combination is designed to suppress sperm production while maintaining physiological testosterone levels.

Proceeds from the round will support late-stage development of NES/T Gel, an investigational hormonal, reversible male contraceptive with first-in-class potential. The financing positions Contraline to advance NES/T through Phase 3 development, where it could potentially become the first approved pharmacologic contraceptive for men.

The candidate recently completed a global Phase IIb clinical trial enrolling 462 couples, with the company reporting encouraging efficacy, tolerability, reversibility, and user acceptability data. Contraline anticipates beginning Phase III development in 2027. In parallel, the company is advancing additional male contraceptive technologies, including ADAM, an investigational, long-lasting, non-hormonal, and reversible contraceptive currently in clinical development.